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Abstract 
Transcriptional control and modulation of calcium fluxes underpin the differentiating properties of 
vitamin D (1,25(OH)2D3). In the latest years however few studies have pointed out the relevance of 
the mitochondrial effects of the hormone. It is now time to focus on the metabolic results of vitamin 
D receptor (VDR) action in mitochondria, which can explain the pleiotropic effects of 1,25(OH)2D3 
and may elucidate few contrasting aspects of its activity. The perturbation of lipid metabolism 
described in VDR knockout mice and vitamin D deficient animals can be revisited based on the 
newly identified mechanism of action of 1,25(OH)2D3 in mitochondria. From the same point of 
view, the controversial role of 1,25(OH)2D3 in adipogenesis can be better interpreted.  
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Abbreviations: VDR, vitamin D receptor; RXR, retinoid X receptor; VDR KO, VDR knockout 
mice; WT, wild type; WAT, white adipose tissue; BAT, Brown adipose tissue; UCP, uncoupling 
protein; THR, thyroid hormone receptor; PPARperoxisome proliferator-activated receptor 
gamma; OCR, oxygen consumption rate; CPT2: carnitine palmitoyltransferase 2; LXR, liver X 
receptor;  DRIP 205/MED1, vitamin D-interacting protein 205/mediator complex subunit 1; TCA 
cycle, tricarboxylic acid cycle; C/EBPCCAAT/enhancer binding protein beta.   
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1. Introduction 
Many biological functions of the active form of vitamin D 1,25(OH)2D3 are mediated by the control 
exerted by its receptor VDR on nuclear transcription. VDR acts as a transcription factor, migrating 
into nuclear compartment upon ligand binding and together with its binding partner retinoid X 
receptor alpha (RXRα) it recruits coactivators or corepressors to enhance or repress the transcription 
of many genes. Although 1,25(OH)2D3 nuclear activity has generally been described as a promoter 
of differentiation, often the effects exerted by 1,25(OH)2D3 are not detectable or even opposite [1-
2]. A defective nuclear function of VDR has been described as the altered switch between 
coactivators and corepressors associated to VDR [3,4], but alone this perturbation does not account 
for the contrasting effects triggered by 1,25(OH)2D3; moreover the non-genomic activity of VDR, 
mainly mediated by calcium fluxes, is responsible for additional effects that may change the 
response to 1,25(OH)2D3. 
1,25(OH)2D3 controls calcium homeostasis through genomic and non genomic pathways. As 
transcriptional factor, vitamin D receptor (VDR) upregulates calcium transporters; for example it 
induces the expression of the ion channel transient receptor potential vanilloid type 6 (TRPV6, the 
main mediator of calcium transport across the plasmamembrane of intestinal epithelium [5]), and it 
increases the messenger of the calcium sensing receptor CaR [6], sensitizing the keratinocytes to 
extracellular calcium and calcium-triggered differentiation. 
The main non genomic action of 1,25(OH)2D3 consists in the regulation of calcium fluxes by direct 
interaction with plasma membrane proteins. In fact VDR localizes to the caveolar domains of 
plasma membrane, like other members of the steroid receptor superfamily, and promotes rapid 
membrane-initiated responses (reviewed in [7,8]). The outcomes of the membrane bound VDR 
activity influence nuclear transcription; for example the opening of voltage-gated calcium channels 
[9-12] or the generation of second messengers (as summarized in [13]) contributes to a concerted 
genomic and non-genomic regulation of many vitamin D-responsive genes. The aim of this review 
is to widen the analysis of the complex cross-talk between nuclear and extranuclear effects of 
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1,25(OH)2D3 mediated by different VDR pools; for this purpose, we discuss the mitochondrial 
effects of 1,25(OH)2D3 and their metabolic consequences. For further details on the activity of 
1,25(OH)2D3, the reader is referred to very comprehensive reviews on vitamin D metabolism 
[14,15],  VDR transcriptional activity [16,17] and regulation [18]. 
 
2. VDR: a nuclear receptor with a penchant for mitochondria 
In addition to the nuclear effects of 1,25(OH)2D3, recently a new mechanism of action has been 
suggested by the described localisation of VDR in mitochondria of platelets, megakaryocytes [19] 
and keratinocytes [20], where the translocation is mediated by the permeability transition pore 
activity [20]. Indeed, the mitochondrial function of VDR has been elucidated by subsequent works 
on cancer cell lines [21], keratinocytes [22] and brown adipocytes [23] that have demonstrated that 
1,25(OH)2D3 suppresses mitochondrial respiration, hence VDR has been defined a gatekeeper of 
mitochondrial respiratory chain activity. The consequences of the negative modulation of 
respiratory chain exerted by VDR are important for cellular bioenergetics as well as for biosynthetic 
pathways; in fact the mitochondrial activity of 1,25(OH)2D3 supports both cell growth and 
differentiation and this newly discovered metabolic effect relies on the switch from oxidative to 
biosynthetic metabolism [21,22]. Given its dual nuclear and mitochondrial activity, it is tempting to 
speculate that 1,25(OH)2D3  has a central role both in the regulation of gene sets and in supporting 
the metabolic requests evoked by nuclear signaling. In fact it is reasonable to think that the 
mitochondrial activity is modulated in order to adapt cellular metabolism to the nuclear 
differentiation program or proliferative nuclear signaling.  
The metabolism that most obviously is affected by the mitochondrial control is the lipidic one; in 
fact both the catabolic pathways and the formation of precursors for biosynthetic purposes take 
place in mitochondria. In this article, we provide an overview of the link between the activity of 
1,25(OH)2D3 and lipid metabolism, and we put forward new and speculative hypotheses on the 
effects of VDR signaling in mitochondria, by suggesting that the combined nuclear and 
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mitochondrial action of 1,25(OH)2D3 might support the metabolism of the adipose tissue and skin 
as well as many others.  
 
3. The lessons learned from VDR knockout mice 
Due to the central role of 1,25(OH)2D3 in calcium homeostasis and deposition in bones, the 
silencing of VDR in knockout (KO) mice causes a defective calcium absorption and skeletal 
remodeling. Three independent models of VDR null mice were generated by disruption of the DNA 
binding domain of VDR, ablating either the first or the second zinc finger (exon 2 and 3, 
respectively) (Tokyo [24], Boston [25], Leuven [26] models); a fourth group (Munchen model [27]) 
produced a mouse that expressed a VDR protein with a deletion of the first zinc finger, thus unable 
to bind DNA, but with normal ligand binding affinity. All the models developed hypocalcemia, 
hypophosphatemia. secondary hyperparathyroidism, severe rickets and osteomalacia [24-27] due to 
the lack of functional VDR. Also the non-genomic effects of VDR were lost [27]. Besides the 
expected hypocalcemic and bone defective phenotype, VDR knockout mice are a good model to 
study the impact of VDR-mediated 1,25(OH)2D3 activity in extra-skeletal tissues and general 
metabolism in vivo, including the role of 1,25(OH)2D3 and VDR in adipogenesis and lipid 
metabolism. Two studies investigated the metabolic phenotype of VDR-null mutant mice [28,29] in 
the Boston model [25]. In these mice the genetic alteration results in a frame shift followed by 
premature termination codon, which generates an apparent instability of the VDR transcript [25]. 
These animals exhibited decreased body weight, diminished body fat, reduced serum levels of 
leptin and lipids (triglycerides and cholesterol), while the calorimetric parameters such as energy 
expenditure, oxygen consumption and CO2 production were increased. At the cellular level, beta-
oxidation was higher in white adipose tissue (WAT), and the expression of carnitine 
palmitoyltransferase 2 (CPT2, the mitochondrial transporter of fatty acids) was increased in the 
knockout animals, compared to the wild type (WT) littermates [28]. An increase in the expression 
of all uncoupling proteins (UCP) in the brown adipose tissue (BAT) was also observed in the VDR 
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KO mice, suggesting an enhanced energy uncoupling in these cells and higher basal energy 
expenditure. Accordingly, treatment of brown adipocytes with 1,25(OH)2D3  downregulated the 
expression of all three UCPs [28]. The inhibitory effect of VDR on UCP expression has been 
demonstrated in studies carried out in human adipose tissues [29] and in hereditary vitamin D-
resistant rickets [30] establishing VDR as a modulator of energy balance in humans. The metabolic 
and molecular perturbations found in primary adipocytes and in the KO mice suggest key action of 
liganded VDR in the mitochondria and explain the lower adipose mass and lower plasma lipid 
profile in the mutant mice.  
A similar lean phenotype was also described in mice lacking the 1-hydroxylase enzyme that 
generates 1,25(OH)2D3 [31], supporting the important role of 1,25(OH)2D3 in lipid metabolism.  
The lean phenotype found in VDR KO model has the same traits as the hyperthyroid metabolism 
described in humans and in mice models of hyperthyroidism [32-35]. This similarity could be 
explained by hypothesizing a competition between VDR and thyroid hormone receptors (THR) on 
cofactors or binding partners that would become limiting in the activity of the hormones. This could 
be the case for RXR alpha, the heterodimerization partner of many steroid receptors; the 
competition over RXR has been demonstrated not only for VDR and THR [36] but also for other 
members of the steroid/nuclear hormone receptor superfamily, such as peroxisome proliferator-
activated receptors (PPAR) and liver X receptor (LXR) [37-40]. Another limiting candidate could 
be the coactivator DRIP 205/MED1 (vitamin D-interacting protein 205/mediator complex subunit 
1), which is necessary for transcriptional activity of both VDR and THR [41,42]. Therefore the lean 
phenotype of VDR KO mice could be the result of a direct effect of VDR silencing and a 
potentiated action of thyroid hormone.  
The observations made in VDR KO mice are confirmed by the opposite results obtained in the 
transgenic mouse model overexpressing the human VDR specifically in the adipose tissue [43], 
which gains adipose mass and reduces energy metabolism compared with the WT counterpart. In 
direct opposition to what described for VDR KO mice, in the transgenic model the investigators 
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found reduced leptin levels, increased circulating cholesterol and decreased calorimetric parameters. 
The overexpression of VDR in the adipocytes led to reduced UCP expression, decreased beta-
oxidation and lipolysis, and glucose intolerance. The metabolic derangement was accompanied by 
suppression of key genes involved in these processes (hexokinase, carnitine palmitoyl transferases, 
lipases). Interestingly enough, when the effect of 1,25(OH)2D3 was analysed in two adipocyte cell 
lines, a direct transcriptional control of these enzymes was not evident, rather suggesting that 
1,25(OH)2D3 influences fatty acid transport, catabolism and glycolysis by indirectly regulating these 
genes [43].   
In conclusion, the analysis of VDR KO and transgenic mice demonstrated that the mitochondrial 
action of 1,25(OH)2D3 is exerted on catabolism of fatty acids and uncoupling. 1,25(OH)2D3 reduces 
lipid utilization from depots and decreases the energy and heat dissipation due to uncoupling 
process. As a consequence, VDR ablation leads to the lean phenotype. The precise mechanism 
through which VDR can control lipid catabolism remained elusive.  
1,25(OH)2D3 controls lipid metabolism also in the skin. VDR KO mice have also defects in 
permeability barrier homeostasis due to a disrupted barrier formation, lipid secretion, and lipid 
composition [44]. The importance of 1,25(OH)2D3 and VDR in the regulation of permeability 
barrier formation is supported also by the observations made in mice deficient in 1α-hydroxylase; 
these animals show an impaired barrier repair after acute disruption due to a decrease in lamellar 
body secretion [45]. 
 
4. The effects of 1,25(OH)2D3 and VDR on mitochondrial activity: the consequences 
on lipid metabolism  
Recent studies have described the influence of 1,25(OH)2D3 on mitochondrial activity. A first work 
has demonstrated that in the human keratinocyte cell line HaCaT the VDR can downregulate the 
transcription of proteins of the respiratory chain and can decrease the mitochondrial membrane 
potential, in other words VDR restrains the activity of mitochondrial respiratory chain [21]. This 
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conclusion is supported by the data presented in another study [23] that measured cellular 
bioenergetics coupled with mitochondrial stress tests by a XF24 Extracellular Flux Analyzer. The 
study investigated mitochondrial respiration in 1,25(OH)2D3-treated human brown adipocytes and 
demonstrated that 1,25(OH)2D3 suppresses basal oxygen consumption rate (OCR), maximal OCR 
and OCR from proton leak. The metabolic modulation exerted by 1,25(OH)2D3 /VDR sustains cell 
proliferation, and indeed several cancer cell lines silenced for VDR are inhibited in their growth 
[21]. One of the consequences of VDR-induced brake on respiratory chain is the rerouting of 
mitochondrial acetyl-CoA towards biosynthesis. In proliferating cells the diversion benefits mainly 
the cholesterol production necessary to proliferation [21], thus the metabolic modulation exerted by 
1,25(OH)2D3/VDR sustains cell growth, and indeed several cancer cell lines silenced for VDR are 
inhibited in their growth [21]. By contrast, in differentiated keratinocytes that upregulate the fatty 
acid biosynthetic pathway the metabolic switch promotes lipid deposition [22]. We can conclude 
that the effects of 1,25(OH)2D3 on mitochondria support differently the metabolism of differentiated 
and proliferating human cells. 
At present, with this novel insight into the modalities of 1,25(OH)2D3 action, we can better 
understand the observations made in VDR KO and 1,25(OH)2D3-deficient models by reinterpreting 
the metabolic data and formulating new hypothesis, summarized in figure 1. VDR downregulates 
respiratory chain activity, curtails the utilization of reducing units and slows down beta-oxidation. 
As consequence, the mitochondrial activity of VDR decreases lipid catabolism and promotes the 
channeling of acetyl-CoA into biosynthetic pathways (figure 1A). Indeed the consequences of VDR 
overexpression are the increased adipose mass and the reduced energy metabolism observed in the 
transgenic mouse model [43]. When VDR activity is lost, in knockout or diet-deficient animals, the 
mitochondrial respiratory activity is enhanced and UCPs expression is higher, leading to the 
observed increased calorimetric parameters [28,29]. The dual control of VDR on respiratory chain 
and UCPs expression is interesting and makes sense, in order to avoid unnecessary uncoupling and 
finely tune a proton gradient which cannot rely only on ATPase activity. Because of this concerted 
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control, the formation and dissipation of proton gradient is balanced. When VDR is ablated, the 
increased respiratory activity enhances the TCA cycle and beta-oxidation rises. The low levels of 
cytosolic malonil-CoA (derived from acetyl-CoA) relieve the inhibition of fatty acid mitochondrial 
import (figure 1B); as consequence, fat is mobilized from depots and catabolized in mitochondria. 
The cachectic phenotype observed in 1,25(OH)2D3-deficient animals is another consequence of the 
increased oxidative metabolism, because muscle wasting is due to aminoacid utilization in TCA 
cycle. 
 
5. 1,25(OH)2D3 activity and adipogenesis 
When the effects of 1,25(OH)2D3 activity are investigated in vitro, both adipogenesis and adipocyte 
differentiation appear to be affected by the hormone, but the observations reach conflicting 
conclusions depending on the cellular model investigated.  
The genome-wide studies based on next-generation sequencing have demonstrated the important 
role of histone modifications and epigenetic modulators in adipogenesis, and have added new 
details on how the cellular context (for example in response to thermogenic signals) can change the 
genomic programming of adipocytes (reviewed in [46]).  
Also the genomic effects of  1,25(OH)2D3 are strongly influenced by the cellular setting. The most 
recent genome-wide analysis of the 1,25(OH)2D3-modulated transcriptome have hightlighted the 
complexity of events that determine the recruitment of VDR/RXR heterodimers and co-activators to 
binding sites often located in the enhancer regions of genes, and have described the interaction with 
general regulators of the chromatin remodeling process (reviewed in [47]). The VDR cistrome 
profile is lineage specific and it is modulated by the cellular status. For example the cellular 
differentiation dictates a remarkable quantitative and qualitative change of the transcriptional 
control exerted by 1,25(OH)2D3.  The studies on osteoblast differentiation [48-51] have described 
the reduction and modification of VDR-dependent transcriptome in differentiated cells: many genes 
become resistant to 1,25(OH)2D3 stimulation and  others change their transcriptional response; the 
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reasons of this plasticity related to cellular status can reside in the enrichment of transcription 
factors at nearby sites that can influence VDR activity and in the rearranged epigenetic landscape 
that can modify the access of VDR to binding motives close to target genes. In turn, bound VDR 
can influence the epigenetic profile of the cell and facilitate cellular transition [47,52].   
Few studies have described the inhibitory effect of 1,25(OH)2D3 on adipogenesis. The analysis of 
the mechanisms underpinning differentiation has been often carried out on the preadipocyte cellular 
model 3T3-L1 cell line, which can be terminally differentiated into mature adipocytes [53]. At time 
zero, the cells are treated with prodifferentiative agents (insulin, glucocorticoids, and 
phosphodiesterase inhibitor) that induce two rounds of cell division, and after two days the cells are 
switched to a differentiation medium containing only insulin. Several studies using the murine 3T3-
L1 preadipocyte cell line have investigated the major transcriptional players in adipogenesis 
[54,55]. The early clonal expansion is driven by C/EBP(CCAAT/enhancer binding protein beta) 
[56] and glucocorticoid receptor, followed by a second cascade of transcription factors such as 
PPAR, which is a primary driver of the adipocyte gene program. In the later stage the 
differentiated cells express the markers characteristic of adipocyte phenotype. 1,25(OH)2D3 inhibits 
in a dose-dependent manner the early events of the adipogenic program (the first 48 hours), whereas 
it is ineffective if administered in the late phase of the differentiation protocol [2]. The effect is 
mediated by the stabilization of VDR protein, by the suppression of PPAR upregulation and the 
antagonization of PPAR activity [2, 57]. The activities of VDR and PPAR are linked and 
influence each other. Indeed VDR overexpression suppresses PPARγ transactivation in brown 
preadipocytes [23] and this negative modulation has been reported for another member of the 
PPARfamily [58]. On the other hand, the overexpression of PPAR attenuates 1,25(OH)2D3-
mediated transactivation of VDR and competes with VDR for their binding partner RXR [37]. 
Moreover 1,25(OH)2D3 downregulates C/EBP gene expression in differentiating 3T3-L1 cells [1]. 
Other studies carried out in a line of brown adipocytes [23] and in the femoral bone marrow derived 
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cell line (BMS2) [59] confirmed that 1,25(OH)2D3  suppresses adipogenesis in the early phase of 
the differentiation process and the effect disappears if the cells are treated after day two of the 
differentiation protocol.Based on these observations we can conclude that 1,25(OH)2D3 acts as 
anti-differentiating agent only in the early events of a differentiation protocol applied to 
proliferating cell lines, by interfering with the activity of key transcription factors.  
On the other hand, the data collected from primary models used in adipogenesis studies show that in 
primary cells committed to adipocyte lineage the 1,25(OH)2D3 exerts a differentiating adipogenic 
effect. Few established models to study adipogenesis start from primary bone cultures in which 
progenitor cells are committed to several mesenchymally derived cell types.  In freshly isolated 
fetal rat calvaria (RC) cell populations the adipocyte differentiation is stimulated by 1,25(OH)2D3 
[60,61]. Moreover the treatment with the hormone increases the frequency of osteoblast/adipocyte 
bipotential progenitors and the number of colonies stained for lipids [62]. The primary bone marrow 
stromal cells are sensitive to 1,25(OH)2D3 treatment that stimulates adipocytic cell differentiation 
[63]. 1,25(OH)2D3 stimulates adipogenesis also in mesenchymal progenitor cells derived from 
normal human adipose tissue [64]. Microarray analysis of the adipogenic process showed that 
nuclear signaling of VDR, while promoting adipogenic differentiation, downregulates genes 
involved in differentiation into other lineages  [64]. 
In conclusion, the effect of 1,25(OH)2D3 on adipogenesis is opposite whether the cellular model 
analysed is a proliferating preadipocyte cell line or a committed primary culture of progenitor cells. 
The differences between the models can be ascribed to the lineage-specific chromatin remodeling 
taking place during differentiation protocols, which can determine the variability of VDR cistrome. 
A different recruitment of VDR and co-activators to DNA can have opposite effects on gene 
transcription. In addition to the genomic effects of its receptor,  we must also consider the results of 
1,25(OH)2D3 activity on cellular metabolism. Based on the observation that the effects of 
1,25(OH)2D3 on mitochondria support differently the metabolism of differentiated and proliferating 
human keratinocytes [21,22], as discussed in section four, similar conclusions can be drawn on 
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adipogenesis, keeping in mind that the metabolic effects of 1,25(OH)2D3 sustain the nuclear 
programming. We propose an integrated genomic and metabolic view that can conciliate the dual 
effect of 1,25(OH)2D3 on adipogenesis; in our model, depicted in figure 2, the chromatin 
reorganization triggered by environmental clues influences VDR cistrome, so that VDR is effective 
on selected genes required by the cellular context, either proliferation or differentiation. At the same 
time, the effects of 1,25(OH)2D3 on mitochondrial metabolism support the specific gene expression 
profile. When the adipogenesis of a preadipocyte cell line is considered, in the early phase of a 
differentiation protocol the stimulation with glucocorticoids, insulin and phosphodiesterase 
inhibitor maintains a proliferative asset; in this phase 1,25(OH)2D3 sustains proliferation since 
acetyl-CoA can be diverted toward cholesterol biosynthesis. As consequence, in this model the 
outcome of 1,25(OH)2D3 treatment in the early phase of differentiation is a decreased lipid 
deposition (figure 2A). In the late events of differentiation, when the cultural conditions change and 
adipogenesis is consolidated, the treatment with 1,25(OH)2D3 can support the differentiated state by 
diverting acetyl-CoA into fatty acid biosynthesis. The VDR seems necessary for lipid accumulation 
in the late phase, since knock-down of the VDR both delays and prevents this process [1,64]. This 
happens despite the low levels of VDR found in differentiated 3T3-L1 cells [1,2], suggesting that 
even barely detectable amount of the receptor are sufficient and necessary to support the adipogenic 
function. 
Instead, when the differentiation protocol is applied to primary cultures from bone, a model in 
which progenitor cells are committed to the adipocyte lineage, 1,25(OH)2D3  supports a nuclear 
differentiation program and facilitates lipid deposition because the mitochondrial acetyl-CoA can be 
used in the fatty acid biosynthetic pathway (figure 2B). In all cases, the metabolic response to 
1,25(OH)2D3 /VDR activity is the increased availability of acetyl-CoA for biosynthetic purposes, 
but the epigenetic reprogramming could be responsible for the biosynthetic fate of this precursor: 
for example the prevalence of SREBP-1 or SREBP-2 activity due to chromatin remodeling could 
potentiate lipogenesis or cholesterologenesis, respectively. In fact several data suggest that SREBP-
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1 primarily regulates fatty acid metabolism and that SREBP-2 is the main regulator of cholesterol 
metabolism [65]. Few studies reported a differential accumulation of SREBP-1 or SREBP-2 under 
different dietary conditions  consistently with each factor performing a preferred metabolic function 
in lipogenesis or cholesterologenesis in the liver [66-68]. A comparison of the genome-wide 
binding profiles for SREBP-1 and SREBP-2 in hepatic chromatin revealed that only 11.7 % of their 
binding sites overlap and demonstrated that under specific conditions they bind mostly to different 
sets of target sites in the liver genome [69]. Future genome-wide studies should integrate the VDR 
cistrome analysis with the examination of the binding profile of the key transcription factors in 
adipogenesis. 
 
6. 1,25(OH)2D3 deficiency in murine models and men: cachectic versus obese 
phenotype 
The lean phenotype observed in VDR KO animals is found also in rats fed with a 1,25(OH)2D3-
deficient diet [70]. The two models show overlapping parameters, although with few differences 
due to calcium imbalance. In fact, whereas VDR KO animals are fed a diet enriched in calcium, 
indeed to avoid indirect metabolic effects, the dietary lack of 1,25(OH)2D3 induces a perturbed 
calcium homeostasis that makes results difficult to interpret; the addition of calcium in this diet 
reverts partially the effects and adds new metabolic variables, such as the increase in insulin levels. 
The common features of animals deficient either in 1,25(OH)2D3 or its receptor are the decreased 
body weight and fat, the reduced levels of leptin and increased expression of uncoupling proteins. 
Whereas in VDR KO is evident the enhanced utilization of fat from depots, in 1,25(OH)2D3-
deficient animals there are also the signs of reduced adipogenesis, because the transcription of 
PPAR and fatty acid synthase is decreased [70]. 1,25(OH)2D3 deficiency affects also muscular 
tissues, which decrease their mass similarly to fat depots. Muscle wasting in 1,25(OH)2D3-deficient 
rats is due to increased muscle protein breakdown [71]. Therefore 1,25(OH)2D3 deficiency leads to 
an unhealthy lean and cachectic phenotype characterized by muscle wasting and reduced adiposity. 
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If low levels of 1,25(OH)2D3 or its receptor lead to the lean phenotype, it would be reasonable to 
expect the opposite result when a diet is fortified with 1,25(OH)2D3. On the other hand, 
1,25(OH)2D3 increases calcium absorption and enhances intracellular calcium utilization, and this 
could stimulate the cellular energy expenditure, could activate the basal metabolism and facilitate a 
lean phenotype. The effects of 1,25(OH)2D3 supplementation have been investigated in models of 
obesity induced by the high fat diet. These studies have reached conflicting conclusions, also 
because different animal models and different supplemented diets have been used. The long-term 
(one year) feeding of mice with a diet high in fat and low in vitamin D3 (the precursor of 
1,25(OH)2D3), calcium, methyl donors and fiber leads to reduced energy expenditure and oxygen 
consumption, impaired glucose clearance and an elevated systemic inflammatory response. In this 
model, elevating dietary vitamin D3 and calcium increases weight gain, fat deposition, and worsens 
the metabolic syndrome [72]. In contrast, both a mice and a rat model fed for a shorter time (ten or 
eight weeks) with a high fat diet benefit from 1,25(OH)2D3 treatment, since 1,25(OH)2D3 
supplementation in mice protects against diet-induced obesity, improves glucose homeostasis and 
lipid oxidation [73], and reduces body weight gain, inhibits lipogenesis and promotes fatty acid 
oxidation in rat liver [74]. 
Clearly, in humans it is not possible to reproduce a VDR KO model. However, a primary deficiency 
or the resistance to 1,25(OH)2D3 is found in some diseases: rickets, for example; unfortunately the 
lipid metabolism has not been investigated in these subjects.  
Clinical studies correlate obesity with 1,25(OH)2D3 deficiency [75-81]; this link is possibly due to a 
reduced synthesis of the active form of vitamin D in obese individuals, or to the sequestration of 
1,25(OH)2D3 in the increased fat tissue found in obesity. Indeed there are evidences that obesity is 
characterized by a decreased expression of the two biosynthetic enzymes of 1,25(OH)2D3  
metabolism, the 25-hydroxylase and the 1-hydroxylase, in human adipose tissue [82]. Moreover 
the high fat diet in mice resulted in a decrease of 25(OH)-vitamin D plasma level [73]. Therefore it 
seems reasonable to hypothesize that obesity and metabolic syndrome are promoters of 
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1,25(OH)2D3 deficiency, although it is unknown the mechanism by which the perturbed lipid 
homeostasis would affect the biosynthetic enzymes. This view is endorsed by the recent bi-
directional Mendelian randomization analysis of 21 adult cohorts, which has demonstrated that 
higher BMI (body mass index) leads to lower 1,25(OH)2D3 status, whereas there is no evidence for 
a causal role of 1,25(OH)2D3 deficiency in the development of obesity [83]. The fact that low levels 
of 1,25(OH)2D3 are not causative of obesity is supported by the irrelevance of 1,25(OH)2D3 
supplementation in clinical trials of obese patients [84-87].  
 
7. Concluding remarks and future perspectives 
Recent studies have highlighted the relevance of 1,25(OH)2D3 activity on mitochondrial 
metabolism, suggesting that many previously described metabolic effects of 1,25(OH)2D3 on 
adipose tissue could be the result of mitochondrial modulation. 
1,25(OH)2D3 exerts a concerted action on nuclear and mitochondrial compartment, and facilitates 
the adaptation of the mitochondrial metabolism to the phenotype generated by nuclear inputs. The 
consequences of 1,25(OH)2D3 action on adipogenesis are dual, because the hormone can support 
both the proliferative phase and the differentiation process of the precursors of adipocytes. 
In differentiated tissues 1,25(OH)2D3 sustains a physiological mitochondrial lipid metabolism by 
two main mechanisms: 
(1) the vitamin D-dependent calcium uptake in tissues enhances lipid catabolism. In fact it has been 
demonstrated that high dietary calcium increases fat oxidation rate and that low calcium intake can be 
associated with higher body fatness (reviewed in [88]). 1,25(OH)2D3 stimulates intestinal calcium 
absorption and renal calcium reabsorption, in order to maintain the serum levels of calcium. Also 
calcium utilization in tissues is influenced by the hormone. Actually many of the metabolic effects of 
1,25(OH)2D3 are mediated by calcium, as demonstrated by the fact that most of the changes 
observed in 1,25(OH)2D3 deficient rats were corrected by calcium supplementation alone [70]. In 
support of the calcium-mediated beneficial effects of 1,25(OH)2D3 , few studies have reported that 
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the supplementation with 1,25(OH)2D3 in association with calcium decreases fat mass in obese 
patients [89,90] and affects glucose metabolism and lipid concentrations in overweight and obese 
vitamin D deficient women [91]. 
(2) 1,25(OH)2D3 exerts a negative transcriptional control on respiratory chain elements and 
uncoupling proteins, in order to withhold respiratory activity and minimize the uncoupling process; 
thus by optimizing the respiratory performance 1,25(OH)2D3 avoids the unnecessary catabolic 
fuelling that would lead to an unhealthy lean cachectic phenotype. This negative control of 
respiratory activity could be superimposed on the antagonism between VDR and THR. Their 
competition for binding partners and co-activators would make their alternation beneficial to the 
optimal respiratory rate. 
In conclusion, 1,25(OH)2D3 is necessary to accumulate lipids and to burn them properly. The effects 
of 1,25(OH)2D3 supplementation could be different depending on dietary calcium content plus the 
individual metabolic phenotype and hormonal balance. Under this perspective, it will be very 
important for future therapeutic strategies to understand what are the causes of reduced biosynthesis 
of 1,25(OH)2D3 in obesity and why 1,25(OH)2D3 is scarcely effective in reducing fat depots in 
obesity.  
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Figure legend 
Figure 1. Schematic presentation of the consequences of mitochondrial activity of VDR on lipid 
metabolism. (A) VDR overexpression downregulates electron transport chain (ETC) and 
uncoupling protein (UCP) expression; the decreased utilization of reducing units NADH and 
FADH2 slows down beta-oxidation. Mitochondrial activity of VDR decreases lipid catabolism and 
promotes the channeling of acetyl-CoA into biosynthetic pathways, whilst the mitochondrial import 
of fatty acids (FA) through carnitine acyltransferase (CAT) is inhibited by the biosynthetic 
precursor malonyl-CoA. (B) The loss of VDR activity reinforces ETC activity and UCP expression; 
TCA cycle and beta-oxidation are enhanced to fuel the boosted respiratory chain. When most of the 
mitochondrial acetyl-CoA is consumed by TCA cycle, very low levels are available in cytosol for 
acetyl-CoA carboxylase to synthesize malonil-CoA, the precursor of the biosynthetic pathway of 
lipids. The transport of fatty acid toward mitochondrial matrix increases because malonil-CoA no 
longer inhibits CAT. AS: ATP synthase. 
Figure 2. The dual effect of 1,25(OH)2D3 on adipogenesis. The mitochondrial effects of 
1,25(OH)2D3 support the nuclear program. (A) In proliferating preadipocyte cell line, in the early 
phase of a differentiation protocol the cultural stimulation maintains the cells in a proliferative 
condition and VDR cistrome adapts to the epigenetic profile imposed by the proliferative context. 
In addition, the mitochondrial effects of 1,25(OH)2D3 support cell growth by shifting acetyl-CoA 
from the oxidative metabolism toward cholesterol biosynthesis. As consequence, 1,25(OH)2D3 
treatment in the early phase of differentiation facilitates proliferation and decreases lipid deposition. 
(B) In primary cultures of cells that are committed to the adipocyte lineage, VDR fits the chromatin 
remodeling induced by the differentiation program and modulates differentiation-specific gene sets. 
In this genomic background that promotes adipogenesis, 1,25(OH)2D3 enhances lipid deposition 
because the mitochondrial acetyl-CoA can be diverted toward the synthesis of fatty acids. ETC: 
electron transport chain;  AS: ATP synthase. 
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